Analysis of Risk Factors for Colon Cancer Progression

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Jun 14

PMID 31190895

Citations 9

Authors

Zhou Yang

Yusheng Chen

Dejun Wu

Zhijun Min

Yingjun Quan

Affiliations

Soon will be listed here.

Abstract

This study aimed to find risk factors for colon cancer progression with bioinformatics methods, and validated by clinical patients. Differentially expressed genes (DEGs) between colon cancer tissues and normal colon tissues were extracted from The Cancer Genome Atlas (TCGA) database using R software, amounted to 8,051. DEGs between pathologic stage I+II and stage III+IV amounted to 373, and were compared with DEGs of cancer/normal analyzed above to get the intersection of both. Ninety-six intersected DEGs were identified and defined as progressive DEGs of colon cancer. Then these 96 progressive DEGs were studied by Gene ontology and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis using the DAVID database and visualizing by R software. A protein-protein interaction (PPI) network and functional modules were established using the STRING database. Further, an overall survival (OS) curve was drawn via the GEPIA website based on the CGA database and six progressive DEGs were found to be involved with OS of colon cancer patients. The Linkedomics website was used for detailed analysis of specific subsets of TNM. Pregnancy specific glycoprotein (PSG), vitamin digestion, and absorption were confirmed to promote the progression of colon cancer. Furthermore, NTF4 was found to be associated with both OS and each subset of TNM; therefore, defined as a key risk factor for colon cancer progression. Further analysis of NTF4 expression using clinical data showed it acted as a key risk factor and diagnosis marker for colon cancer progression. NTF4 is a risk factor contributing to colon cancer progression and associated with overall survival.

Citing Articles

A triterpenoid (corosolic acid) ameliorated AOM-mediated aberrant crypt foci in rats: modulation of Bax/PCNA, antioxidant and inflammatory mechanisms.

Al-Medhtiy M, Mohammed M, Raouf M, Al-Qaaneh A, Jabbar A, Abdullah F J Mol Histol. 2024; 55(5):765-783.

PMID: 39122895 DOI: 10.1007/s10735-024-10229-x.

A chronic stress-induced microbiome perturbation, highly enriched in , promotes colorectal cancer growth and metastasis.

Zhao L, Hou X, Feng Y, Zhang Y, Shao S, Wu X Int J Med Sci. 2024; 21(5):882-895.

PMID: 38617000 PMC: 11008488. DOI: 10.7150/ijms.90612.

lncRNA USP30-AS1 sponges miR-765 and modulates the progression of colon cancer.

Li C, Liang X, Liu Y World J Surg Oncol. 2022; 20(1):73.

PMID: 35260141 PMC: 8905834. DOI: 10.1186/s12957-022-02529-x.

Molecular characterization of colorectal cancer: A five-gene prognostic signature based on RNA-binding proteins.

Liang Q, Du X, Mao L, Wang G Saudi J Gastroenterol. 2021; 27(4):223-233.

PMID: 34169901 PMC: 8448017. DOI: 10.4103/sjg.sjg_530_20.

The value of miR-510 in the prognosis and development of colon cancer.

Hang J, Wei F, Yan Z, Zhang X, Xu K, Zhu Y Open Med (Wars). 2021; 16(1):795-804.

PMID: 34036176 PMC: 8126670. DOI: 10.1515/med-2021-0251.

References

Saito T, Nagai M, Ladanyi M . SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Res. 2006; 66(14):6919-27. DOI: 10.1158/0008-5472.CAN-05-3697. View

Cunningham D, Atkin W, Lenz H, Lynch H, Minsky B, Nordlinger B . Colorectal cancer. Lancet. 2010; 375(9719):1030-47. DOI: 10.1016/S0140-6736(10)60353-4. View

De Las Rivas J, Fontanillo C . Protein-protein interactions essentials: key concepts to building and analyzing interactome networks. PLoS Comput Biol. 2010; 6(6):e1000807. PMC: 2891586. DOI: 10.1371/journal.pcbi.1000807. View

Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N . Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clin Cancer Res. 2011; 17(7):1741-52. DOI: 10.1158/1078-0432.CCR-10-1890. View

Zhivotovskiy A, Kutikhin A, Azanov A, Yuzhalin A, Magarill Y, Brusina E . Colorectal cancer risk factors among the population of South-East Siberia: a case-control study. Asian Pac J Cancer Prev. 2012; 13(10):5183-8. DOI: 10.7314/apjcp.2012.13.10.5183. View

Yatsuoka T, Nishimura Y, Sakamoto H, Tanaka Y, Kurozumi M . [Lymph node metastasis of colorectal cancer with submucosal invasion]. Gan To Kagaku Ryoho. 2014; 40(12):2041-3. View

Azim Jr H, Peccatori F, Brohee S, Branstetter D, Loi S, Viale G . RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res. 2015; 17:24. PMC: 4374174. DOI: 10.1186/s13058-015-0538-7. View

Wang L, Xu Y, Luo C, Sun J, Zhang J, Lee M . MAGEA10 gene expression in non-small cell lung cancer and A549 cells, and the affinity of epitopes with the complex of HLA-A(∗)0201 alleles. Cell Immunol. 2015; 297(1):10-8. DOI: 10.1016/j.cellimm.2015.05.004. View

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

10.

Maine E, Westcott J, Prechtl A, Dang T, Whitehurst A, Pearson G . The cancer-testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion. Oncotarget. 2016; 7(12):14708-26. PMC: 4924746. DOI: 10.18632/oncotarget.7408. View

11.

Ferrer-Mayorga G, Gomez-Lopez G, Barbachano A, Fernandez-Barral A, Pena C, Pisano D . Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer. Gut. 2016; 66(8):1449-1462. PMC: 5530491. DOI: 10.1136/gutjnl-2015-310977. View

12.

Shi Y, Huang X, Chen G, Wang Y, Zhi Q, Liu Y . Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells. Oncotarget. 2016; 7(30):48027-48037. PMC: 5216997. DOI: 10.18632/oncotarget.10338. View

13.

Moriarity A, OSullivan J, Kennedy J, Mehigan B, McCormick P . Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol. 2016; 8(4):276-93. PMC: 4952023. DOI: 10.1177/1758834016646734. View

14.

Yang L, Hu S, Tan J, Zhang X, Yuan W, Wang Q . Pregnancy-specific glycoprotein 9 (PSG9), a driver for colorectal cancer, enhances angiogenesis via activation of SMAD4. Oncotarget. 2016; 7(38):61562-61574. PMC: 5308672. DOI: 10.18632/oncotarget.11146. View

15.

Shahinian J, Fuellgraf H, Tholen S, Mastroianni J, Knopf J, Kuehs M . Pregnancy Specific β-1 Glycoprotein 1 is Expressed in Pancreatic Ductal Adenocarcinoma and its Subcellular Localization Correlates with Overall Survival. J Cancer. 2016; 7(14):2018-2027. PMC: 5118665. DOI: 10.7150/jca.15864. View

16.

Barry E, Peacock J, Rees J, Bostick R, Robertson D, Bresalier R . Vitamin D Receptor Genotype, Vitamin D3 Supplementation, and Risk of Colorectal Adenomas: A Randomized Clinical Trial. JAMA Oncol. 2016; 3(5):628-635. PMC: 5580351. DOI: 10.1001/jamaoncol.2016.5917. View

17.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

18.

Li Q, Li Y, Xu J, Wang S, Xu Y, Li X . Aldolase B Overexpression is Associated with Poor Prognosis and Promotes Tumor Progression by Epithelial-Mesenchymal Transition in Colorectal Adenocarcinoma. Cell Physiol Biochem. 2017; 42(1):397-406. DOI: 10.1159/000477484. View

19.

Vasaikar S, Straub P, Wang J, Zhang B . LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2017; 46(D1):D956-D963. PMC: 5753188. DOI: 10.1093/nar/gkx1090. View

20.

Yuzhalin A, Urbonas T, Silva M, Muschel R, Gordon-Weeks A . A core matrisome gene signature predicts cancer outcome. Br J Cancer. 2018; 118(3):435-440. PMC: 5808042. DOI: 10.1038/bjc.2017.458. View